^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MTAP (Methylthioadenosine Phosphorylase)

    i
    Other names: MTAP, Methylthioadenosine Phosphorylase, S-Methyl-5'-Thioadenosine Phosphorylase, MSAP, 5’-Methylthioadenosine Phosphorylase, MTA Phosphorylase, MTAPase, C86fus, Epididymis Secretory Sperm Binding Protein, Epididymis Luminal Protein 249, MeSAdo Phosphorylase, HEL-249, DMSMFH, DMSFH, LGMBF, BDMF
    1d
    IDE397-001: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (clinicaltrials.gov)
    P1, N=169, Active, not recruiting, IDEAYA Biosciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Trodelvy (sacituzumab govitecan-hziy) • IDE397
    2d
    Distinction of thymic carcinoma and type B3 thymoma using ancillary biomarkers. (PubMed, Pathologica)
    CD5 and CD117 are the best markers for TC. While the addition of other markers (i.e., BAP1 loss, MTAP loss and CDKN2A deletion) might be useful in cases negative for CD5 and CD117, rare cases of type B3 thymoma might harbor these alterations.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • CD5 (CD5 Molecule)
    |
    CDKN2A deletion • KIT expression
    9d
    A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, BeOne Medicines | N=44 --> 63
    Enrollment change • First-in-human
    |
    MTAP (Methylthioadenosine Phosphorylase)
    10d
    Pediatric Fourth Ventricular Atypical Meningioma With a Whorling-Sclerosing Pattern: A Report of a Rare Tumor. (PubMed, Int J Surg Pathol)
    The tumor was negative for a CDKN2A/B homozygous deletion and a TERT promoter mutation. Post-surgery, the patient showed immediate improvement in symptoms and was asymptomatic at the time of discharge and follow-up.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion
    10d
    mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. (PubMed, Cell Rep Med)
    Single-cell transcriptomics further reveals that the combination reprograms effector T cells toward memory-like states with expanded TCR diversity. Collectively, this study proposes a combinatorial mRNA-based strategy and provides mechanistic insights for augmenting ACT through mtApoptosis priming.
    Journal
    |
    MTAP (Methylthioadenosine Phosphorylase)
    14d
    An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting | N=140 --> 29 | Trial completion date: Dec 2028 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    14d
    Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors. (PubMed, Cancers (Basel))
    Our findings demonstrate that MTAP deletion is an infrequent but genomically coherent event in solid tumors, characterized by a canonical 9p21 co-deletion pattern. This real-world analysis underscores the importance of comprehensive genomic profiling to identify patients who may benefit from emerging MTAP-directed therapies.
    Journal • Real-world evidence • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • MAT2A (Methionine Adenosyltransferase 2A)
    |
    TMB-L • CDKN2A deletion • MTAP deletion
    16d
    First reported case in Brazil of intraventricular pilocytic astrocytoma in an adult patient with literature review. (PubMed, Discov Oncol)
    This case illustrates a rare intraventricular PA in an adult, confirmed through clinical, radiological, and histopathological integration. It emphasizes the importance of including PA in the differential diagnosis of intraventricular tumors in adults and may contribute to guiding recognition and management of rare ventricular tumors in this population.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • ATRX (ATRX Chromatin Remodeler) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    IDH1 mutation • IDH1 R132
    17d
    A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (clinicaltrials.gov)
    P2, N=260, Not yet recruiting, Bristol-Myers Squibb
    New P2 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    Opdivo (nivolumab) • carboplatin • gemcitabine • temozolomide • albumin-bound paclitaxel • pemetrexed • navlimetostat (BMS‐986504) • Opdualag (nivolumab/relatlimab-rmbw) • daraxonrasib (RMC-6236) • pumitamig (BNT327)
    17d
    Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard-of-Care and Emerging Therapeutic Strategies. (PubMed, J Gastroenterol Hepatol)
    Emerging immunotherapies targeting Claudin18.2 and CXCR4 offer hope to overcome tumor resistance. Together, these strategies underscore the promise of molecular stratification, synthetic lethality, and novel targets to improve pancreatic cancer survival.
    Review • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • HRD (Homologous Recombination Deficiency) • CLDN18 (Claudin 18) • NRG1 (Neuregulin 1) • MTAP (Methylthioadenosine Phosphorylase) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    HRD • KRAS wild-type • MTAP deletion • RAS wild-type • NRG1 fusion